STOCK TITAN

Daxor Corp. - DXR STOCK NEWS

Welcome to our dedicated news page for Daxor (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Daxor's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Daxor's position in the market.

Rhea-AI Summary
Daxor Corporation (NASDAQ: DXR) will be showcasing its innovative blood volume analysis (BVA) diagnostic at the Technology and Heart Failure Therapeutics Conference. BVA guided treatment in heart failure has demonstrated significant reductions in readmissions, mortality, and length of stay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (DXR) announces two significant customer transactions in January 2024, showcasing a strong start to the year. The new wins include a four-year lease agreement for the BVA analyzer at a network of 24 hospitals and a purchase at a 200-bed independent hospital. Dr. Aaron Earles praises the BVA technology for its impact on patient care. CEO Michael Feldschuh highlights the company's focus on commercialization and expanding market reach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) announces the expansion of blood volume analysis (BVA) through new analyzer purchases and the utilization of Daxor’s ezBVA Lab service. Q4-2023 sales wins include BVA analyzer purchases and rentals at various healthcare organizations, leading to a strong position for growth in 2024. CEO Michael Feldschuh emphasizes the focus on broadening commercial reach, integrating with new hospital systems, and strengthening clinical and health economic evidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
earnings
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) will be exhibiting at the SNMMI Mid-Winter and ACNM Annual Meeting to raise awareness and educate members about their blood volume measurement technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) announces its participation in the Society for Critical Care Medicine 2024 Critical Care Congress, presenting an opportunity to extend its presence in the critical care field. The CEO and President, Michael Feldschuh, emphasizes the value of Daxor's diagnostic in guiding care to optimal volume in areas such as heart failure and critical care. Chief Scientific Officer Jonathan Feldschuh highlights compelling evidence affirming the efficacy of direct blood volume measurement in enhancing patient outcomes within critical care settings, citing a randomized controlled trial showing a 66% decrease in patient mortality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (DXR) receives a second patent (U.S. Patent No. 11,862,311 B2) from the United States Patent and Trademark Office for a distinctive clinical guidance system for blood volume management. The system utilizes unique blood volume metrics and related clinical measures to create support guidance for fluid management interventions, targeting common and costly conditions such as heart failure, critical care, hypertension, surgical blood loss, and sepsis. Daxor's Chief Scientific Officer, Jonathan Feldschuh, highlights that the new patented system makes fluid management decisions significantly easier, driving better outcomes and empowering clinicians to make more effective treatment decisions. Daxor's CEO and President, Michael Feldschuh, emphasizes the company's mission to advance healthcare by enabling optimal fluid management and equipping physicians with tools for more effective diagnosis and treatment, ensuring a distinct advantage in the market with next-generation products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The new Daxor BVA device directly quantifies the intravascular blood, red blood cell and plasma volume, providing clinicians with actionable information to achieve optimal fluid management for their patients. Compared to the current Daxor BVA-100 system, the new Daxor BVA is designed to be three times faster, simpler to operate, completely portable, and capable of performing bedside analysis, making it easier for healthcare providers to integrate this innovative diagnostic into their clinical workflow. The CEO and President, Michael Feldschuh, stated that the new analyzer will significantly improve care and outcomes in medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) Announces Positive Results from NIH-Sponsored Study at AHA Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.05%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) announces the granting of a patent for remote blood volume monitoring using smartwatches and wearable devices. The patent covers methods for monitoring patients with various medical conditions, ensuring ongoing care is optimized based on evolving blood volume status. Daxor's Chief Scientific Officer highlights the significance of the patent in protecting innovations in applying blood volume measurement to specific medical conditions and situations. The company's CEO emphasizes the focus on innovation and next-generation technologies, supported by funding from the NIH and DoD, to add significant intellectual property assets for future product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
Rhea-AI Summary
Leading clinicians highlight significant outcome improvements with Daxor's blood volume analysis innovative technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
Daxor Corp.

Nasdaq:DXR

DXR Rankings

DXR Stock Data

36.52M
2.06M
57.6%
1.53%
0.19%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Oak Ridge

About DXR

the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.